Finance
Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data
Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a clinical update for its pivotal Phase 3 RESTORATiVE303 study of VE303 for the […]